# Zenas BioPharma, Inc. (ZBIO) FY2026 YTD Q2 Statement of Cash Flows

- Company: Zenas BioPharma, Inc. (ZBIO)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-13, accession number 0001104659-26-095448
- Page: https://plicit.ai/financials/zbio/fy2026-ytd-q2-cash-flow
- Chart image: https://plicit.ai/charts/zbio-fy2026-ytd-q2-cash-flow-sankey.png

## Chart details

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Dec 31, 2025**: 110,641,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- **Operating activities**: negative 132,433,000 US dollars. Net cash used.
- **Net loss**: negative 192,443,000 US dollars
- **Operating lease liabilities**: negative 481,000 US dollars
- **Accrued expenses**: 2,975,000 US dollars
- **Accounts payable**: 461,000 US dollars
- **Prepaid expenses and other assets**: negative 5,373,000 US dollars
- **Non-cash lease expense**: 533,000 US dollars
- **Acquired in-process research and development**: 30,000,000 US dollars
- **Stock-based compensation expense**: 17,814,000 US dollars
- **Non-cash interest expense on convertible senior notes**: 280,000 US dollars
- **Depreciation expense**: 10,000 US dollars
- **Non-cash interest expense on senior secured term loan**: 2,088,000 US dollars
- **Net amortization of premiums and accretion of discounts on investments**: negative 1,397,000 US dollars
- **Non-cash interest expense on royalty obligation**: 13,100,000 US dollars
- **Investing activities**: negative 256,093,000 US dollars. Net cash used.
- **Purchases of property and equipment**: negative 2,000 US dollars
- **Purchases of investments**: negative 408,330,000 US dollars
- **Proceeds from sales and maturities of investments**: 182,239,000 US dollars
- **Payments of milestones achieved pursuant to license agreements**: negative 30,000,000 US dollars
- **Financing activities**: 475,536,000 US dollars. Net cash provided.
- **Payments of other offering costs for the ATM offering and equity offering**: negative 527,000 US dollars
- **Payments of debt issuance costs for the senior secured term loan and convertible senior notes**: negative 1,934,000 US dollars
- **Proceeds from the issuance of convertible senior notes, inclusive of underwriters' exercise of the overallotment option in full, net of commissions**: 223,100,000 US dollars
- **Proceeds from senior secured term loan, net of discount**: 73,500,000 US dollars
- **Proceeds from exercise of stock options**: 1,173,000 US dollars
- **Proceeds from issuance of common stock, net of commissions - ATM Program**: 71,532,000 US dollars
- **Proceeds from issuance of common stock, net of commissions - Equity Offering**: 108,100,000 US dollars
- **Proceeds from issuance of common stock under employee stock purchase plan**: 592,000 US dollars
- **Operating adjustment reconciliation**: 199,694,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 477,997,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 438,332,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: negative 1,074,000 US dollars
- **Ending cash on Jun 30, 2026**: 196,577,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- **Cash sources and uses**: 586,177,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: 85,936,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
- **Operating cash flow**: negative 132,433,000 US dollars. Operating cash flow used in the free cash flow calculation.
- **Cash purchases of property, plant and equipment**: 2,000 US dollars. These cash purchases are already included in investing activities above.
- **Free cash flow**: negative 132,435,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net loss −$192.44M + net operating adjustments $60.01M = operating cash −$132.43M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 132,433,000 US dollars minus 2,000 US dollars equals negative 132,435,000 US dollars.